COMMUNIQUÉS West-GlobeNewswire

-
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
13/08/2018 -
VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen’s AV-101 for Potential Anti-Suicidal Effects in Veterans
13/08/2018 -
Pure Global Cannabis, Inc. Uniquely Positioned to Lead Cannabis Health & Wellness Market-- CFN Media
13/08/2018 -
Hemispherx Updates Stockholders, Highlighting Ampligen’s Role in Enhancing Immunotherapeutic Therapies
13/08/2018 -
AIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund
13/08/2018 -
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis
13/08/2018 -
First Choice Healthcare Solutions to Host Second Quarter 2018 Results Conference Call on August 15, 2018
13/08/2018 -
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2018
13/08/2018 -
Transactions under Novozymes’ stock buyback program
13/08/2018 -
Allscripts Payerpath™ Achieves EHNAC Healthcare Network Accreditations
13/08/2018 -
CTD Holdings Announces Expanded Access Protocol using Intravenous Trappsol® Cyclo™ for Alzheimer’s Disease
13/08/2018 -
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2018
13/08/2018 -
HealthEC Launches Opioid Analytics Module at 2018 MESC Conference
13/08/2018 -
Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit
13/08/2018 -
Arsanis Reports Financial Results for Second Quarter 2018
13/08/2018 -
BioSig Technologies Completes Private Placement
13/08/2018 -
Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency
13/08/2018 -
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer
13/08/2018 -
Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights
13/08/2018
Pages